Eiger BioPharmaceuticals, Inc.
Close the sale of the Priority Review Voucher
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 31 Jan 2021
- Delivered
- January 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“PRV sale for $95M expected to close in January 2021”
What we found
Evidence strength A What the grades mean
The company confirmed in multiple SEC filings that the sale of the Priority Review Voucher to AbbVie for $95 million closed in January 2021.
-
A Eiger BioPharmaceuticals, Inc. 10-K filed 2021-03-09
“The transaction closed in January 2021.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- PRV sale
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Eiger BioPharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C305253-021277 · Corrections policy